Analysts project H.B. Fuller is 19% undervalued with a $73.29 price target based on 2029 revenue forecasts, though risks include weak demand and raw material cost pressures.
H.B. Fuller shares appear undervalued by 37.1% per DCF models, though P/E ratios remain fair amidst activist pressure and potential acquisitions.
Royal Bank of Canada increased its stake in H. B. Fuller by 2,694% in Q1, acquiring 651,585 shares. The chemical company reported strong quarterly earnings with EPS of $1.41 and revenue growth of 5.8%
TradingKey analyzes H.B. Fuller Company stock, highlighting healthy fundamentals and a 'Buy' consensus with a $73.91 target price. The report suggests range-bound swing trading for the chemical firm d
H.B. Fuller shares declined 11% post-earnings, underperforming the S&P 500 despite strong second-quarter fiscal 2026 results with adjusted earnings up 19% year-over-year. The company retains a Zacks R
H.B. Fuller reported strong Q2 and H1 results attracting activist investor Ancora Holdings Group, with Simply Wall St valuing shares 21% below fair value due to strategic acquisitions and restructurin
H.B. Fuller stock closed at US$64.60 with mixed valuation signals; narratives suggest undervaluation while DCF models indicate overvaluation, citing raw material cost risks.
Brown Advisory Inc. reduced its stake in specialty chemicals firm H. B. Fuller by 6.7% in Q4. The company recently exceeded earnings estimates, increased dividends, and retains strong institutional ow
H.B. Fuller shares rose 8.18% over 90 days, sparking mixed valuation signals with fair value estimates ranging from $59.80 to $70.43. Investors face risks from weak demand and rising raw material cost
H.B. Fuller Co shares fell 3.3% to $59.84, yet remain modestly undervalued with a GF Score of 83. Insider buying of $0.3 million signals confidence in the adhesive manufacturer's future despite modera
ChemBrief